ERBB2 and gastric cancer: We chose the human epidermal growth factor receptor 2 (HER2)-targeted mAb trastuzumab (IgG), also known as Herceptin, which is used to treat HER2-positive breast and gastric cancer by inhibiting the HER2 signaling pathway and thereby limiting proliferation [50, 51].